Results 1 to 10 of about 19,412 (203)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma

Respiratory Medicine Case Reports, 2018
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge.
Takayuki Shiroyama, Shingo Nasu, Satomu Morita   +2 more
exaly   +4 more sources

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies [PDF]

Therapeutic Advances in Medical Oncology, 2021
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations.
Christiane Bickert, Kathrin Kahnert, Diego Kauffmann-Guerrero, Jeremias Götschke, Zulfiya Syunyaeva, Jürgen Behr, Amanda Tufman   +6 more
doaj   +2 more sources

Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer [PDF]

EMBO Molecular Medicine
Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, show robust clinical efficacy in EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), yet acquired resistance remains inevitable.
Zhen Chen, Dongsheng Wang, Songqing Fan, Qiming Wang, Yong Huang, Pan Du, Shidong Jia, Suresh S Ramalingam, Shi-Yong Sun   +8 more
doaj   +2 more sources

Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells

Cell Death Discovery, 2023
The efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has been evaluated in glioblastoma (GBM) through preclinical and clinical trials.
Lulu Hu, Ji Shi, Dachuan Shen, Xingyue Zhai, Dapeng Liang, Jing Wang, Chunrui Xie, Zhiyu Xia, Jing Cui, Feng Liu, Sha Du, Songshu Meng, Haozhe Piao   +12 more
doaj   +2 more sources

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

Radiation Oncology, 2021
Background The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations and brain ...
Xiaoyang Zhai, Wanhu Li, Ji Li, Wenxiao Jia, Wang Jing, Yaru Tian, Shuhui Xu, Yuying Li, Hui Zhu, Jinming Yu   +9 more
doaj   +1 more source

Osimertinib [PDF]

Reactions Weekly, 2021
  +8 more sources

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction

Molecular Oncology, 2020
Osimertinib, a third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), provides marked clinical benefit for patients with EGFR‐activating mutations.
Rui Han, Shuai Hao, Conghua Lu, Chong Zhang, Caiyu Lin, Li Li, Yubo Wang, Chen Hu, Yong He   +8 more
doaj   +1 more source

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

Thoracic Cancer, 2020
Background Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC).
Daisuke Hayakawa, Fumiyuki Takahashi, Yoichiro Mitsuishi, Ken Tajima, Moulid Hidayat, Wira Winardi, Hiroaki Ihara, Koichiro Kanamori, Naohisa Matsumoto, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Kazuya Takamochi, Takuo Hayashi, Yoshiyuki Suehara, Ikuko Takeda Nakamura, Toshihide Ueno, Shinji Kohsaka, Hiroyuki Mano, Kazuhisa Takahashi   +19 more
doaj   +1 more source

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

Frontiers in Pharmacology, 2022
Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a star medication used to treat non-small-cell lung carcinomas (NSCLCs).
Zheng Yuan, Xin Yu, Siyang Wu, Xiaonan Wu, Qiutao Wang, Wenhao Cheng, Weiyu Hu, Chen Kang, Wei Yang, Yingfei Li, Xiao-Yang Zhou   +10 more
doaj   +1 more source

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Journal of Translational Medicine, 2022
Background EGFR-mutant non-small cell lung cancer (NSCLC) is prone to leptomeningeal metastasis (LM) after Tyrosine kinase inhibitors (TKIs) treatment. Our previous study suggested that osimertinib plus bevacizumab was safe and effective in LM from EGFR ...
Yali Yi, Jing Cai, Peng Xu, Le Xiong, Zhiqin Lu, Zhimin Zeng, Anwen Liu   +6 more
doaj   +1 more source